Novartis AG (NVS)
Pre-Market: 04:15AM EDT
- GlobeNewswire
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)1Potentially clinically meaningful improvements in both PFS and OS were observed among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses are ongoing1Results support continued study of canakinumab i
- Zacks
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
- Zacks
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
